Physician profile
James Bailey
NPI 1669458782
$4,120.54
in general payments reported to CMS, 2019-2025
44 companies · $755 in 2025
The $755 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,731 · 2020: $261 · 2022: $220 · 2023: $437 · 2024: $716 · 2025: $755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,908.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,908.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $648.51 | 2019-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $369.23 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $331.81 | 2023-2025 | Qulipta, Ubrelvy, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $286.77 | 2019-2025 | Entyvio, Trintellix |
| Pfizer INC. | $277.66 | 2019-2024 | |
| Lilly USA, LLC | $254.74 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $205.76 | 2019-2022 | |
| Allergan, INC. | $192.07 | 2019-2020 | |
| Astellas Pharma US INC | $176.09 | 2019-2023 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.90 | 2019-2025 | Jardiance |
| Gilead Sciences, INC. | $90.82 | 2019-2024 | |
| Abbott Laboratories | $90.18 | 2019-2024 | Freestyle Libre 3 |
| Amgen INC. | $84.52 | 2019-2024 | Krystexxa |
| Phathom Pharmaceuticals, INC. | $80.25 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $73.32 | 2023 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $58.34 | 2023-2025 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $57.64 | 2019-2025 | Capvaxive, Gardasil 9, Vaxelis |
| Corcept Therapeutics | $56.51 | 2025 | Korlym |
| Glaxosmithkline, LLC. | $53.31 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Genentech USA, INC. | $50.02 | 2019-2020 | |
| Amarin Pharma, INC. | $44.88 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $43.98 | 2019 | |
| Ironshore Pharmaceuticals INC. | $33.15 | 2019 | |
| Dexcom, INC. | $32.57 | 2022-2024 | Dexcom G6 Transmitter |
| Corium, LLC | $29.84 | 2024 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $27.39 | 2019-2025 | Camzyos |
| Vertical Pharmaceuticals, LLC | $23.97 | 2019 | |
| Shire North American Group INC | $23.17 | 2019 | |
| Sunovion Pharmaceuticals INC. | $21.67 | 2019 | |
| Pinnacle Biologics, INC | $20.07 | 2020 | |
| Sanofi-Aventis U.S. LLC | $19.98 | 2019 | |
| Inspire Medical Systems, INC. | $18.03 | 2025 | Inspire |
| Seqirus USA INC | $17.18 | 2025 | Flucelvax, Fluad |
| Lundbeck LLC | $16.00 | 2025 | Rexulti |
| Bavarian Nordic A/S | $15.70 | 2025 | Vivotif |
| Cranial Technologies, INC | $15.19 | 2023 | Doc Band |
| Medtronic Minimed, INC. | $15.09 | 2020 | |
| Neos Therapeutics, Lp | $14.66 | 2023 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $14.64 | 2022 | |
| Medtronic, INC. | $14.18 | 2025 | Inceptiv |
| Daiichi Sankyo INC. | $13.97 | 2023 | Injectafer |
| Tms Neurohealth Centers INC. | $13.11 | 2025 | Tms Neurohealth Centers INC. |
| Sanofi Pasteur INC. | $12.04 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.